recherche française mobilisée sur le covid-19
chercheuse en laboratoire travaille sur le covid-19
©Maridav - stock.adobe.com

Covid-19 vaccine: a French platform for clinical evaluation

To contribute to the progress of researches in the fight against Covid-19, the Inserm (French Institute for Health and Medical Research) just launched COVIREIVAC, a large-scale clinical assessment platform for vaccine candidates against the virus.

Thanks to the support of various partners, such as REACTing (a multidisciplinary consortium of scientific teams and excellence labs), the French Public Health Centre (Santé publique France), the University Hospital Centres and the National College of Teachers General Practitioners, the COVIREIVAC project could be achieved. The project will allow to methodologically test vaccine and obtain data about their capacity to induce an immune response, and about their safety for patients.

 

A scientific and strategic necessity for France

As the Inserm shows during the presentation of its project to the press, “research for a vaccine against Covid-19 is booming, and many candidate vaccines already reach clinical evaluation stage”. Up to now, the World Health Organisation (WHO) listed over 140 candidate vaccines, of which 17 are in “clinical development” stage. So, as the Institute point out, the participation of France to clinical trials has become “a scientific and strategic necessity to ensure access to a secure and efficient vaccine” for its population.

 

The COVIREIVAC project

To act pragmatically and so France accesses candidate vaccines, it was necessary according to the Inserm to implement a “single service desk for industrial and academic stakeholders”. This desk should help “evaluate these products in order to guarantee the feasibility of clinical trials to industrial stakeholders engaged in the process and negotiate the terms for production and marketing”. The implementation of the project also implies the creation of a scientific committee that will provide details on the most interesting candidates vaccines, including their “efficiency, safety and production capacity”.

 

 

 

A network of clinical centres on the territory

In this precise case, and to answer the scientific and strategic necessity, the COVIREIVAC project will implement a “quality clinical evaluation” of various candidate vaccines against Covid-19. In order to reach this goal, the project will use an already existing network of 24 hospitals and clinics throughout France. This network should lead to an “extended participation from the French population to vaccine trials”.

A collaboration with other European countries “to extend the scheme and allow clinical trials to a more extended scale” is also considered by the Institute.

Follow the main steps to come study in France

Discover
Published on: 31/07/2020 à 16:51
Updated : 31/07/2020 à 16:54
newsletter
Register to the Newsletter